Fibroblast Growth Factor 2 - Pipeline Review, H2 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 30, 2019--
The “Fibroblast Growth Factor 2 - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
According to the recently published report ‘Fibroblast Growth Factor 2 - Pipeline Review, H2 2019’; Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) pipeline Target constitutes close to 10 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Basic fibroblast growth factor also known as bFGF or FGF2 is a member of the fibroblast growth factor family. This protein plays an important role in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth. Diseases associated with FGF2 include corneal neovascularization and pulmonary capillary hemangiomatosis.
Reasons to buy
Key Topics Covered:
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/w48nxp
View source version on businesswire.com:https://www.businesswire.com/news/home/20191230005148/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 12/30/2019 06:18 AM/DISC: 12/30/2019 06:18 AM